

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED**

**精優藥業控股有限公司\***

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 00858)**

### **POSITIVE PROFIT ALERT**

This announcement is made by Extrawell Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules (“**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (“**Board**”) of the Company wishes to inform the shareholders of the Company (“**Shareholders**”) and potential investors that based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended 31 March 2015 (“**Management Accounts**”), the Group expects to record a substantial increase in profit for the year ended 31 March 2015 when compared with the profit recorded by the Group for the year ended 31 March 2014.

Based on the preliminary assessment of the Management Accounts, the consolidated profit attributable to equity holders of the Company for the year ended 31 March 2015 is expected to record a significant increase as compared with that for the corresponding year ended 31 March 2014. Such increase was primarily attributable to, among other things, gain on disposal of the Group’s 51% equity interest in Smart Ascent Limited as completed in July 2014 and fair value changes in the Group’s investment in convertible bonds in aggregate of about HK\$300 million. Details regarding the disposal and the convertible bonds are disclosed in the Company’s announcement dated 28 July 2014 and circular dated 27 June 2014.

The Company is still in the process of preparing the annual results of the Group for the year ended 31 March 2015. The information as set out above is only based on a preliminary assessment by the Board on the information currently available to it, including the Management Accounts, which have not been finalized and are subject to audit or further review by the Company's auditors. The annual results of the Company for the year ended 31 March 2015 are expected to be published before the end of June 2015.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Extrawell Pharmaceutical Holdings Limited**  
**Xie Yi**  
*Chairman*

Hong Kong, 15 June 2015

*As at the date of this announcement, the executive directors are Dr. Xie Yi, Dr. Lou Yi, Mr. Cheng Yong, Ms. Wong Sau Kuen and Mr. Liu Kwok Wah and the independent non-executive directors are Mr. Fang Lin Hu, Mr. Xue Jing Lun and Ms. Jin Song.*

\* *For identification purpose only*